Director
CurrentFounded with the aim of curing and preventing cancer, Xylonix is developing, the first-in-class, onco-parthanatos agents. These compounds initiate strong T cell and NK cell immunity responses making current immunotherapies stronger and more reliable. We are now broadening our scope to comprehensively target prevention, symptomatic management and cure autoimmune disorders, turbo cancers and infectious diseases.